Absci Corp

public$ABSI View Live Feed →

Total Raised

Contracts

Patents

PAC Giving

Government Contracts & Awards

No recent government contracts or awards found.

Proprietary Tech & Patents

No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).

Form D Funding

No recent SEC Form D filings found.

Market Intelligence & News

SeekingAlpha Sep 9, 2026

Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add Up

Absci is rated SELL, as its valuation is highly concentrated on ABS-201 with limited partner revenue and an early-stage pipeline. Click for more on ABSI.

SeekingAlpha Sep 8, 2026

Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)

Absci is upgraded to Buy after strong Phase 1 ABS-201 AGA data, solid PK/safety, and 2026â27 catalysts. Read the latest analysis on the stock here.

Yahoo Aug 12, 2026

Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation

Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci’s recent early Phase 1 ABS-201 update and Eli Lilly’s US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareholder...

Congressional Trades in $ABSI

No disclosed congressional trades found in $ABSI.

Insider Trades (Form 4)

Insider

Somaratne Ransi Mudalinayake

CMO, Head of R&D

Insider

Political Giving

No disclosed PAC contributions found for this entity.

Factual Connections

Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.

Upgrade to Pro